Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
Rabah Redjoul, Anne Le Bouter, Florence Beckerich, et al.
The Lancet (2021) Vol. 398, Iss. 10297, pp. 298-299
Open Access | Times Cited: 117

Showing 1-25 of 117 citing articles:

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Peter Bergman, Ola Blennow, Lotta Hansson, et al.
EBioMedicine (2021) Vol. 74, pp. 103705-103705
Open Access | Times Cited: 204
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 180
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 107
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1760-1774
Open Access | Times Cited: 89
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
Rabah Redjoul, Anne Le Bouter, Vincent Parinet, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 10, pp. e681-e683
Open Access | Times Cited: 74
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2014-2034
Open Access | Times Cited: 72
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
Alexis Maillard, Rabah Redjoul, Marion Klemencie, et al.
Blood (2021) Vol. 139, Iss. 1, pp. 134-137
Open Access | Times Cited: 68
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Nico Gagelmann, Francesco Passamonti, Christine Wolschke, et al.
Haematologica (2021) Vol. 107, Iss. 8, pp. 1840-1849
Open Access | Times Cited: 67
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, et al.
American Journal of Hematology (2021) Vol. 97, Iss. 1, pp. 30-42
Open Access | Times Cited: 61
Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review
Maria da Conceição Rodrigues Fernandes, Germana Silva Vasconcelos, Amanda Campelo Lima de Melo, et al.
Molecular Immunology (2023) Vol. 156, pp. 148-155
Open Access | Times Cited: 34
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Julia E. Wiedmeier, Madiha Iqbal, Allison Rosenthal, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 6, pp. 456-462
Open Access | Times Cited: 23
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Lorenzo Canti, Stéphanie Humblet‐Baron, Isabelle Desombere, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 51
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 33
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra, Elitza S. Theel
Journal of Clinical Microbiology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 31
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101983-101983
Open Access | Times Cited: 21
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Per Ljungman, Gloria Tridello, José Luís Piñana, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 542-554
Closed Access | Times Cited: 8
Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Anne‐Claire Mamez, Amandine Pradier, Federica Giannotti, et al.
Bone Marrow Transplantation (2021) Vol. 56, Iss. 12, pp. 3094-3096
Open Access | Times Cited: 37
SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
Béatrice Clémenceau, Thierry Guillaume, Marianne Coste‐Burel, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 448-448
Open Access | Times Cited: 27
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
Dafna Yahav, Ruth Rahamimov, Tiki Mashraki, et al.
Transplant International (2022) Vol. 35
Open Access | Times Cited: 26
Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
Yurie Kobashi, Yuzo Shimazu, Takeshi Kawamura, et al.
PLoS ONE (2022) Vol. 17, Iss. 6, pp. e0269917-e0269917
Open Access | Times Cited: 26
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
Chenghao Ge, Kelei Du, Mingjie Luo, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children's cancer and Leukaemia Group (CCLG), and British Infection Association (BIA)
PDE Miller, SR Patel, Roderick Skinner, et al.
Journal of Infection (2022) Vol. 86, Iss. 1, pp. 1-8
Open Access | Times Cited: 24
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
Patrick Harrington, Katie J. Doores, Chandan Saha, et al.
Cancer Cell (2021) Vol. 39, Iss. 11, pp. 1448-1449
Open Access | Times Cited: 32
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy
Thomas Gastinne, Amandine Le Bourgeois, Marianne Coste‐Burel, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 2, pp. 360-362
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top